Hasil Pencarian  ::  Simpan CSV :: Kembali

"Latar Belakang: Kolitis ulseratif distal merupakan kolitis ulseratif yang paling sering ditemukan. Dibandingkan dengan terapi oral, terapi topikal kurang banyak digunakan pasien. Satu studi melaporkan bahwa terapi oral digunakan pada 35,6% pasien sedangkan terapi topikal hanya digunakan pada 6,7% pasien. Namun demikian, berbagai studi yang menilai terapi topikal tersebut memberikan hasil yang inkonsisten.Tujuan: Mengetahui efektivitas pemberian beberapa terapi topikal dalam tatalaksana kolitis ulseratif distal derajat ringan dan sedang.Sumber Data: Penelusuran studi dilakukan hingga September 2020 pada empat basis data: PubMed/MEDLINE, Cochrane, ProQuest, dan SCOPUS. Pencarian sekunder dilakukan dengan teknik snowballing pada referensi studi yang ditemukan, pencarian melalui ClinicalTrial.Gov, pencarian melalui Garuda, dan Global Index Medicus.Seleksi Studi: Studi randomized controlled trial (RCT). Subyek merupakan pasien kolitis ulseratif distal derajat ringan dan sedang. Studi dengan intervensi yang dilakukan berupa terapi topikal 5-ASA enema, kortikosteroid enema, asam hialuronat enema. Luaran efektivitas yang dinilai berdasarkan respon klinis, remisi klinis, profil keamanan dan efek samping terapi tersebut. Tidak dilakukan pembatasan bahasa maupun waktu.Ekstraksi Data: Ekstraksi data dilakukan oleh kedua peninjau secara independen. Hasil: Respon klinis ditunjukkan pada pemberian 5-ASA enema dibandingkan plasebo enema (RR 2.48, IK 95% 1.81-3.38, p<0.00001). NNT 3 (IK 95% 2-4). Remisi klinis ditunjukkan pada pemberian kortikosteroid enema dibandingkan plasebo enema (RR 1.98, IK 95% 1.59-2.45, p<0.00001). NNT 5 (IK 95% 4-7). Tidak terdapat perbedaan antara pemberian 5-ASA enema bila dibandingkan dengan kortikosteroid enema baik Beclomethasone diproprionate enema (RR 1.04, IK 95% 0.70-1.54, p=0.85) dan Budesonide enema (RR 1.26, IK 95% 0.91-1.73, p=0.16). Asam hialuronat enema merupakan terapi topikal baru yang cukup aman dan efektif namun membutuhkan penelitian lebih lanjut dengan kualitas penelitian yang lebih baik. Terapi topikal memiliki profil keamanan yang baik. Sebagian besar adverse event ringan dan tidak signifikan.Kesimpulan: 5-ASA enema dan kortikosteroid enema efektif dalam mencapai respon dan remisi klinis bila dibandingkan dengan plasebo. Tidak terdapat perbedaan antara 5-ASA enema bila dibandingkan dengan kortikosteroid enema

---

Background: Distal ulcerative colitis is the most common ulcerative colitis. Compared with oral therapy, topical therapy is less used by patients. One study reported that oral therapy was used in 35.6% of patients whereas topical therapy was used in only 6.7% of patients. However, studies assessing this topical therapy have yielded inconsistent results. Objective: To determine the effectiveness of topical therapy in the management of mild and moderate distal ulcerative colitis. Data Source: Study searching was done through September 2020 on four databases: PubMed / MEDLINE, Cochrane, ProQuest, and SCOPUS. Secondary searching was done by snowballing method of the study references, searching through ClinicalTrial.Gov, Garuda, and the Global Index Medicus. Study Selection: A randomized controlled trial (RCT). Subjects were mild and moderate distal ulcerative colitis patients. Intervention studies included topical 5-ASA enema therapy, corticosteroid enema, and hyaluronic acid enema. The effectiveness outcome was assessed based on clinical response, clinical remission, safety profile and side effects of the therapy. There are no language or time restrictions. Data Extraction: Data extraction was done by both reviewers independently. Results: Clinical response was shown in 5-ASA enema versus placebo enema (RR 2.48, CI 95% 1.81-3.38, p <0.00001). NNT 3 (CI 95% 2-4). Clinical remission was shown in corticosteroid enema versus placebo enema (RR 1.98, CI 95% 1.59-2.45, p <0.00001). NNT 5 (CI 95% 4-7). There was no difference between 5-ASA enema administration when compared to corticosteroid enema, Beclomethasone diproprionate enema (RR 1.04, 95% CI 0.70-1.54, p = 0.85) and Budesonide enema (RR 1.26, CI 95% 0.91 -1.73, p = 0.16). Hyaluronic acid enema is a new topical therapy that is quite safe and effective in achieving clinical response and remission but requires further research with better research quality. Topical therapies have a good safety profile. Most of the adverse events were mild and insignificant. Conclusion: 5-ASA enemas and corticosteroid enemas were effective in achieving clinical response and remission when compared to placebo. There was no difference between 5-ASA enemas when compared with corticosteroid enemas"

"Latar Belakang: Tingginya pertumbuhan kasus keganasan ginekologi dan organ panggul menyebabkan penggunaan terapi radiasi meningkat. Akan tetapi, terapi radiasi juga cukup banyak menimbulkan proktitis radiasi sebesar 30%. Tatalaksana menggunakan agen topikal seperti SCFA, sukralfat, steroid, formalin, dan 5-ASA diketahui memiliki hasil yang baik, namun belum banyak studi yang membandingkan terapi mana yang lebih superior. Tujuan: Menilai efektivitas beberapa terapi topikal terhadap perbaikan gejala klinis dan gambaran endoskopi pasien proktitis radiasi. Sumber Data: Pencarian utama dilakukan secara elektronik pada basis data PubMed, Cochrane/CENTRAL, Scopus, dan Science Direct antara September hingga November 2020. Pencarian sekunder dilakukan secara snowballing pada referensi studi yang terkait, dan melalui register uji klinis yang tersertifikasi lainnya seperti Global Index Medicus, Garba Rujukan Digital (GARUDA), ClinicalTrial.gov, dan International Clinical Trials Registry Platform (ICTRP) WHO. Seleksi Studi: Studi uji klinis acak terkontrol dengan intervensi terapi topikal dibandingkan plasebo atau terapi topikal lainnya atau kombinasi terapi medikamentosa, yang menilai luaran berupa respon gejala klinis dan gambaran endoskopi, serta dapat disertai luaran lain, ataupun tidak. Tidak ada batasan terhadap tahun publikasi dan bahasa. Penilaian judul, abstrak, dan studi dilakukan oleh dua orang peninjau independen. Dari total 1786 studi, didapatkan 9 studi memenuhi kriteria eligibilitas.Ekstraksi Data: Ekstraksi data dilakukan oleh dua peninjau independen dan dikonfirmasi pada peninjau ketiga. Konfirmasi data dilakukan dengan menghubungi peneliti dari studi terkait. Tidak didapatkan data tambahan. Hasil: Studi yang melaporkan efektivitas terapi berupa banyaknya jumlah subjek yang mengalami perbaikan atau penurunan skor klinis dan endoskopi dirangkum secara kualitatif. Masing-masing studi saling membahas antar terapi, dan memiliki heterogenitas yang tinggi. Dua studi mengenai formalin dapat dilakukan meta-analisis dengan hasil perbaikan klinis dan endoskopi, namun tidak bermakna terhadap dua studi tersebut (RR 0.97, 95% CI: 0.82-1.15) dan tidak terdapat terapi yang lebih superior dibanding terapi lain dalam meta-analisis tersebut. Empat studi yang membahas formalin 4% memiliki kualitas hasil studi menengah dengan risiko bias rendah. Terdapat 3 dari 9 studi yang membandingkan terapi SCFA dengan plasebo sehingga sulit untuk menyimpulkan terapi mana yang berefek lebih baik, dan memiliki risiko bias tidak jelas, namun dengan jumlah pasien yang sedikitsehingga kualitas studi rendah. Satu studi mengenai efektivitas sukralfat menunjukkan hasil bermakna dengan estimasi risiko rendah (RR 0.57, 95% CI: 0.35-0.92, P = 0.02). Akan tetapi studi mengenai 5-ASA topikal tidak ditemukan dalam inklusi telaah sistematis ini. Secara umum, kualitas hasil studi berdasarkan GRADE dapat dimasukkan ke dalam kategori sedang.Kesimpulan: Penggunaan terapi SCFA enema, formalin topikal, steroid topikal, dan sukralfat enema efektif dalam memperbaiki gejala klinis dan gambaran endoskopi proktitis radiasi. Namun, hingga saat ini belum ada studi klinis berkualitas baik sehingga sulit untuk menilai terapi yang terbaik. Sedangkan dari 2 studi formalin 4% yang dapat dilakukan meta-analisis, menunjukkan bahwa tidak ada terapi yang lebih superior dibandingkan lainnya. Selain itu, tidak ditemukan tidak ditemukan efek samping berat pada penggunaan terapi SCFA enema, formalin topikal, steroid topikal, dan sukralfat enema dalam mengobati proktitis radiasi.

---

Background: The high incidence of gynecological and pelvic malignancies has led to the usage of radiation therapy. Nonetheless, radiation therapy also causes a significant complication, about 30% of radiation proctitis. Treatments using topical agents such as SCFA, sucralfate, steroids, formalin, and 5-ASA are known to have good results. However, there are only a few studies comparing the superiority of those therapies.

Objectives: To assess the effectiveness of topical therapies in the clinical and endoscopic improvement of radiation proctitis patients.

Data Sources: Primary searching was conducted on electronic databases such as PubMed, Cochrane/CENTRAL, Scopus, and Science Direct between September and November 2020. Secondary searching was done by snowballing method on the relevant study references and through other certified clinical trial registries (Global Index Medicus, Garba Digital Reference (GARUDA), ClinicalTrial.gov, and WHO's International Clinical Trials Registry Platform (ICTRP).

Study Selection: A randomized controlled trial comparing topical therapies versus placebo or other topical therapies or combination with medical therapies that evaluating the clinical response and endoscopic response. There is no restriction regarding the year of publication and language. Each study were assessed by two independent reviewers. From a total of 1,786 studies identified, 9 studies met the eligibility criteria.

Data Extraction: Data extraction was performed by two independent reviewers and confirmed by a third reviewer. Data confirmation was made by contacting the first researchers from related studies. No additional information was obtained.

Results: Studies reporting the effectiveness of therapy in the form of a large number of subjects experiencing improvement or reduction in clinical symptoms and endoscopy were summarized qualitatively. Each study discussed the therapies and the heterogeneity that could not be calculated due to the different outcomes. Two studies on formalin were subject to meta-analysis with clinical and endoscopy improvement. However, they were not significant in the two studies (RR 0.97, 95% CI: 0.82-1.15), and no better treatment compared with others in those studies. Further, four studies discussing 4% formalin had medium study quality results with a low risk of bias. There are 3 out of 9 studies that compared SCFA therapy with placebo so it is difficult to conclude which therapy has a better effect, and has an unclear risk of bias, but with a small number of patients so that the quality of the study is low. One study using sucralfate showed significant results with a low-risk estimate (RR 0.57, 95% CI: 0.35-0.92, P = 0.02). However, the study of topical 5-ASA was not found in the inclusion of this systematic review. The level of evidence for the majority of outcomes was downgraded using GRADE to a moderate level, due to imprecision and study limitation.

Conclusion: The usage of SCFA enema, topical formalin, topical steroid and sucralfate enema are effective in improving the clinical and endoscopic response in radiation proctitis patient. However, until now, there are no good quality studies, making it difficult to prove the best therapy. A meta-analysis from 2 studies using 4% formalin versus irrigation and antibiotics, shows no therapy is superior to another. Otherwise, no serious side effects were found in the usage of these topical therapies"

"Latar belakang: Asma merupakan penyakit ditandai peradangan saluran napas kronik. Satu dari tiga kasus tidak memberikan respon adekuat. Modalitas alternatif terapi  asma adalah magnesium inhalasi. Inhalasi magnesium memiliki efek samping sistemik minimal. Oleh karena itu, peran magnesium inhalasi perlu diteliti lebih lanTujuan: Penelitian bertujuan untuk mengetahui efektivitas dan keamanan pemberian magnesium inhalasi pada pasien dewasa mengalami  asma akut.Metode: Penelusuran literatur dilakukan dua peneliti independen melalui: PubMed/ MEDLINE, Google Scholar, ProQuest, dan Cochrane dengan kata kunci “magnesium inhalasi” dan “serangan asma” dalam bahasa Inggris dan Indonesia. Pencarian manual dan snowballing dilakukan di portal data nasional. Studi yang dimasukkan adalah uji acak terkontrol mengenai perbandingan magnesium inhalasi dengan terapi standar pada serangan asma akut. Penilaian efektivitas berdasarkan parameter readmisi, tanda vital, perbaikan klinis, serta fungsi paru, sedangkan keamanan berdasarkan parameter efek samping. Protokol telaah sistematis didaftarkan pada PROSPERO.Hasil: Lima artikel diikutsertakan dalam telaah sistematis. Dua artikel diikut-sertakan menilai aspek  readmisi. Tiga studi  menilai hubungan magnesium terhadap tanda vital pasien. Dua studi menilai tingkat keparahan penyakit dan perbaikan klinis. Studi menunjukkan tidak terdapat hubungan bermakna pemberian magnesium inhalasi pada aspek readmisi pasien (RR 1; IK 95% 0.92 - 1,08; p= 0,96), dan saturasi oksigen (MD  1,82; IK 95%: -0.89 - 4.53; p= 0.19). Ada penurunan bermakna laju napas pasien  (MD -1,72; IK 95% -3,1 -0.35; p= 0.01), dan perbaikan gejala pada pasien  (RR 0.29; IK95% 0.18 - 0.47; p <0.001). Ada peningkatan bermakna efek samping pasien magnesium inhalasi (HR 1.56; IK 95% 1.05 – 2.32; p= 0.32). Efek samping relatif ringan  berupa hipotensi dan rasa mual. Kesimpulan: Magnesium inhalasi memperbaiki  klinis pasien asma terutama gejala, laju napas, dan fungsi paru.  Magnesium inhalasi dikatakan aman jika diberikan pada pasien, namun hati-hati penggunaan pada pasien hipotensi.

---

Background:  Asthma is a disease characterized by chronic airway inflammation. Asthma occurs to many people worldwide. One third of asthmatic case did not respond adequately to standard therapy (Short Acting Beta Agonist, Anticholinergic, Corticosteroid). One of alternative treatment of asthma is inhaled magnesium.  Theoretically, inhaled magnesium is thought to have less systemic side effect and could act directly to respiratory tract. However, the role of inhaled magnesium therapy is not established yet.

Objective: This review is made to evaluate the effectiveness and safety of nebulized magnesium in adult with acute asthma attack.

Methods: Literature search was conducted by two independent investigators through online databases: PubMed/MEDLINE, Cochrane, ProQuest, and Google scholar using the keywords “inhaled magnesium” and “asthma” in English and Indonesian. Manual searches and snowballing were carried out through national data portals and medical faculty e-libraries. Journal articles included in this study are randomized controlled trials that observed inhaled magnesium in adult with acute asthma attack. All the protocol of this systematic review has been registered in PROSPERO.

Result: There are five articles included in this review. Two of them evaluate the effect of magnesium in term of readmission, three of the studies measures effect of magnesium in vital sign, and two of them evaluate the effect of magnesium in term of severity of asthma There is no significant difference in readmission rate and oxygen saturation in magnesium group compared to control (RR 1; 95% CI 0.92 to 1,08; p= 0,96 and MD 1,82; 95% CI -0.89 to 4.53; p= 0.19, respectively). There is significant reduction of respiratory rate and clinical severity in magnesium (MD -1,72; 95% CI   -3,1 to 0.35; p= 0.01, RR 0.29; 95% CI 0.18 to 0.47; p <0.001, respectively). There was a higher risk of side effect in magnesium group (HR 1.56; 95%CI 1.05 to 2.32; p= 0.03). However, the side effect is relatively mild such as hypotension and nausea.

Conclusion: Inhaled magnesium improves clinical outcome for patient with asthma attack especially lung function, improvement of clinical outcome, and lung function. Moreover, Inhaled magnesium is considered safe to be given to asthmatic patient. However, the inhaled magnesium is given with caution in patient with hypotension."

"Tujuan: Melakukan telaah sistematis untuk membandingkan terapi hidrokortison dan hidrokortison, asam askorbat, dan tiamin (HAT) sebagai ajuvan pada tingkat mortalitas pasien syok septik. Metode: Pencarian komprehensif dilakukan menggunakan empat pangkalan data (PubMed, EMBASE, Scopus, and Cochrane) menggunakan kata kunci spesifik hingga tanggal 18 Mei 2022. Semua studi yang dipublikasikan mengenai penggunaan terapi HAT pada pasien syok septik dikumpulkan dan ditelaah. Hasil: Dua studi uji acak terkendali, satu studi kontrol kasus, dan satu studi kohort yang melibatkan 635 pasien. Terapi HAT ditemukan tidak signifikan dalam menurunkan angka kematian di ICU (RR 0.89 95% CI [0.60 sampai 1.32], p=0.56), angka kematian di rumah sakit (RR 1.2 95% CI [0 ,90 sampai 1.59], p= 0,21), dan mortalitas 28 hari (RR 0,95, 95% CI [0,56 hingga 1,58], p=0,83) Kesimpulan: Tidak ditemukan perbedaan signifikan dalam mortalitas pada kelompok yang menggunakan HAT bila dibandingkan dengan terapi hidrokortison. Registrasi: ID pendaftaran PROSPERO untuk penelitian ini adalah CRD42022296055 (https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=296055).

---

Objective: We systematically reviewed the comparison between hydrocortisone and hydrocortisone-ascorbic acid-thiamine combined therapy (HAT) as adjuvant in the mortality rate of septic shock patients. Method: Four databases (PubMed, EMBASE, Scopus, and Cochrane) are comprehensively searched using specific keywords up to 18th May 2022. All published studies on the use of HAT on septic shock patients were collected and reviewed Results: Two randomized controlled trials, one case control study and one cohort study enrolling 635 patients were included. HAT therapy was found to be not significant in reducing the ICU mortality rate (RR 0,89 95% CI [0,60 to 1,32], p=0,56), hospital mortality rate (RR 1.2 95% CI [0,90 to 1,59], p=0,21), and 28 days mortality (RR 0,95, 95% CI [0,56 to 1,58], p=0,83). Conclusion: No significant difference in mortality was found in the HAT group when compared with hydrocortisone therapy. Trial registration: PROSPERO registration ID for this study is CRD42022296055 (https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=296055)."

"Latar Belakang. Prediksi mortalitas pada kelompok lanjut usia yang semakin meningkat jumlahnya akan memberikan banyak manfaat bagi kesehatan. Cystatin C ditunjukkan memiliki kemampuan sebagai prediktor mortalitas pada beberapa studi. Studi-studi mengenai kemampuan prediksi cystatin c masih sangatlah beragam dan belum ada telaah sistematis untuk menilai kemampuannya dalam memprediksi mortalitas jangka panjang pada kelompok lansia.Tujuan. Penelitian ini bertujuan untuk menilai kemampuan cystatin c sebagai prediktor mortalitas semua sebab dan mortalitas kardiovaskular jangka panjang pada kelompok lanjut usia.Metode. Studi ini merupakan telaah sistematis dan meta-analisis dari studi kohort prospektif observasional. Pencarian studi dilakukan di PubMed, Cochrane, Scopus, EBSCOHost, dan Proquest serta pencarian menual. Kriteria inklusi berupa lansia minimal berusia 65 tahun dengan data cystatin c serum tercantum, kematian semua sebab sebagai luaran. Waktu follow up minimal 5 tahun. Seleksi studi dilakukan berdasarkan alur dari PRISMA. Penilaian kualitas studi dan risiko bias dinilai menggunakan Newcastle Ottawa Scale untuk studi kohort. Hasil studi ditampilkan dalam bentuk deskriptif serta Forest plot.Hasil. Dari 609 studi hasil pencarian, didapatkan 12 studi yang memenuhi kriteria: 5 studi menilai kematian semua sebab, 3 studi menilai kematian kardiovaskular saja, dan 4 studi menilai keduanya. Sebanyak 6 studi dengan kualitas baik dan 6 studi kualitas sedang setelah dilakukan penilaian. Hasil meta-analisis menunjukkan kadar Cystatin C yang tinggi meningkatkan risiko mortalitas jangka panjang akibat semua sebab [HR: 1,74 (95% CI: 1,48 – 2,04); p < 0,00001)] dan mortalitas jangka panjang kardiovaskular [(HR: 2,01 (95% CI: 1,63 – 2,47); p < 0,00001)] pada lansia. Kemampuan prognostik cystatin c tergolong moderat [AUC 0,70 (95% CI: 0,68-0,72); p = 0,02)].

---

Background. Prediction of mortality in growing aged-population will offer several benefits for health sector. Cystatin C, which has long been known as biomarker to more accurately evaluate glomerular filtration rate in elderly, has also been shown to predict mortality from several studies. Studies regarding its predictive ability were vastly varied and there has not been systematic review to examine its ability in predicting long-term mortality in elderly population.

Objectives. This study aimed to evaluate Cystatin C performance as predictor for all-cause and cardiovascular mortality among elderly population.

Methods. A systematic review of prospective cohort studies was performed. Literature searching was done in major databases such as PubMed, Cochrane, Scopus, EBSCOhost, and Proquest. Manual searching was also performed. Inclusion criteria were studies involving elderly age 65 or older, cystatin c serum levels available, all-cause mortality as outcome, and 5-years minimum of follow-up. Study selection was performed according to PRISMA algorithm. Newcastle Ottawa Scale for cohort study was used to assess primary studies’ quality and risk of bias. Study results were presented in descriptive tables and Forest plot.

Results. Initial searching revealed 609 hits with 12 studies eligible for the review: five studies evaluated all-cause mortality, three studies evaluated cardiovascular mortality, and four studies evaluated both. Meta-analysis showed that high cystatin c levels increasing risk of long-term all-cause mortality [(HR: 1.74 (95% CI: 1.48 – 2.04); p < 0.0001)] and cardiovascular mortality [HR: 2.01 (95% CI: 1,63 – 2,47); p < 0,0001)]. The prognostic ability of cystatin c was considerably moderate [AUC 0.70 (95% CI: 0.68-0,72); p = 0.02].

Conclusion. Cystatin C was able to predict long-term mortality in elderly population."

"Tesis ini disusun untuk mengetahui manfaat dari penambahan terapi latihan berfokus skapula pada pasien dengan gangguan rotator cuff dengan luaran primer berupa perbaikan keluhan nyeri dan kemampuan fungsional. Penelitian ini adalah penelitian telaah sistematis dan meta-analisis. Studi dijaring dari database MEDLINE, Embase, CENTRAL, dan PEDro disertai pencarian tambahan melalui registry studi klinis dan referensi dari penelitian-penelitian topik serupa. Kriteria eligibilitas penelitian ini meliputi studi uji klinis acak terkendali tanpa batasan waktu publikasi, partisipan dewasa yang memiliki spektrum kelainan rotator cuff, dan membandingkan terapi latihan berfokus skapula dibandingkan terapi konvensional non-bedah lain atau tanpa terapi. Gangguan rotator cuff akibat cedera traumatik akut, sekunder akibat kelainan neurologis dan/atau keganasan, kelainan struktur skeletal pada bahu, serta yang memiliki riwayat tindakan pembedahan pada kompleks bahu dieksklusikan. Dua peneliti secara independen melakukan seleksi studi dan mengevaluasi risiko bias masing-masing studi menggunakan skala PEDro. Total didapatkan delapan studi dengan total 422 partisipan diinklusikan di penelitian ini dengan risiko bias “fair” hingga “good” berdasarkan skala PEDro. Dari meta-analisis didapatkan latihan berfokus skapula memberikan luaran perbaikan nyeri dan kemampuan fungsional yang lebih baik dibandingkan kontrol (MD -0,84 p<0,001 dan SMD -0,58 p<0,001) khususnya jika diberikan selama lebih dari delapan minggu. Secara kesimpulan, terapi latihan berfokus skapula memberikan perbaikan terhadap keluhan nyeri dan kemampuan fungsional pasien dengan gangguan rotator cuff.

---

This thesis aims to determine the effect of adding scapular-based therapeutic exercise for patient with rotator cuff pathology with the primary outcome being improvement in pain and functional ability. The research design is systematic review and meta-analysis. Studies were searched from MEDLINE, Embase, CENTRAL and PEDro database in addition to clinical registry search and references searching from affiliated studies. Eligibility criteria of this research include randomized clinical trial with no time restriction, adult participant with rotator cuff pathology and study comparing effect of scapular-based therapeutic exercise versus other non-surgery intervention or no intervention. Rotator cuff pathology due to traumatic injury, neurological and/or malignancy disease, structural abnormalities of shoulder and history of shoulder surgery were excluded. Two reviewers independently select the study and did risk of bias evaluation using PEDro scale. In total, eight studies with 422 participants were included with risk of bias “fair” to “good” based on PEDro scale. From meta-analysis, scapular-based therapeutic exercise resulted in better improvement in pain and functional ability compared to control (MD -0,84 p<0,01 and SMD -0,58 p<0,01) especially if given as intervention for at least eight weeks. In conclusion, scapular-based therapeutic exercise is shown to be be more effective in improving shoulder pain and functional ability for patient with rotator cuff pathology."

"Latar Belakang: Poket periodontal merupakan karakteristik periodontitis. Scaling dan root planing merupakan standar emas untuk perawatan periodontitis. Antimikroba lokal tambahan direkomendasikan pada pasien dengan kedalaman probing ≥5 mm. Tujuan: Untuk mengetahui efektivitas klorheksidin dibandingkan dengan antimikroba lokal lainnya pada periodontitis. Metode: Pencarian dilakukan dengan menggunakan panduan Preferred Reporting Items for Systematic Review and Meta Analysis (PRISMA). Meta-analisis dilakukan pada studi yang memenuhi kriteria inklusi setelah penilaian risiko bias. Hasil: Meta-analisis antara chip klorheksidin dan antimikroba lain menunjukkan perbedaan rata-rata kedalaman probing setelah satu bulan sebesar 0,58 mm (p<0,00001) sedangkan setelah tiga bulan perbedaan rata-rata kedalaman probing adalah 0,50 mm (p=0,001), indeks plak 0,01 (p=0,94) dan indeks gingiva -0,11 mm (p=0,02). Antara gel chlorhexidine dan antimikroba lainnya menunjukkan perbedaan rata-rata kedalaman probing 0,40 mm (p=0,30), indeks plak 0,20 mm (p=0,0008) dan indeks gingiva -0,04 mm (p=0,83) setelah satu bulan. Kesimpulan: Chip klorheksidin lebih efektif pada indeks gingiva dibandingkan antimikroba lainnya setelah tiga bulan. Antimikroba lainnya lebih efektif daripada chip klorheksidin pada kedalaman probing setelah satu dan tiga bulan, dan dari gel klorheksidin pada indeks plak setelah satu bulan.

---

Background: Periodontal pockets are characteristic of periodontitis. Scaling and root planing is the gold standard for periodontitis treatment. Additional local antimicrobials are recommended in patients with a probing depth of ≥5 mm.

Objective: To determine the effectiveness of chlorhexidine compared to other local antimicrobials in periodontitis.

Method: Searches were conducted using the Preferred Reporting Items for Systematic Reviews and Meta Analysis (PRISMA) guidelines. Meta-analysis was performed on studies that met inclusion criteria after risk of bias assessment.

Results: Meta-analysis between chlorhexidine chips and other antimicrobials showed a mean difference in probing depth after one month of 0.58 mm (p<0.00001) whereas after three months the mean difference in probing depth was 0.50 mm (p=0.001), index plaque 0.01 (p=0.94) and gingival index -0.11 mm (p=0.02). Between chlorhexidine gel and other antimicrobials showed a mean difference in probing depth of 0.40 mm (p=0.30), plaque index of 0.20 mm (p=0.0008) and gingival index of -0.04 mm (p=0.83) after one month.

Conclusion: Chlorhexidine chips were more effective on the gingival index than other antimicrobials after three months. The other antimicrobials were more effective than chlorhexidine chips on probing depth after one and three months, and than chlorhexidine gels on plaque index after one month."

"Latar Belakang: Disfungsi ereksi (DE) adalah salah satu penyakit sering ditemukan pada mereka yang menderita penyakit ginjal stadium akhir (ESRD). Meskipun transplantasi ginjal memperbaiki masalah ini pada beberapa pasien, sebanyak 20 hingga 50% penerimanya terus menderita DE. Sampai saat ini, literatur mengenai efek transplantasi ginjal terhadap DE masih kontroversial. Mayoritas penelitian menunjukkan bahwa pasien mendapatkan kembali fungsi ereksi setelah transplantasi ginjal, sedangkan penelitian lain menunjukkan efek minimal transplantasi terhadap status DE. Kami melakukan tinjauan sistematis untuk merangkum efek transplantasi ginjal terhadap status DE.Metode: Pencarian literatur sistematis di PubMed, Cochrane, dan Scopus, dilakukan pada bulan April 2020 dengan menggunakan kata bebas dan istilah MeSH. Kami memasukkan semua penelitian prospektif yang menyelidiki skor IIEF sebelum dan sesudah transplantasi pada penerima transplantasi ginjal dengan DE.Hasil: Pencarian database awal di PubMed dan Google Scholar menghasilkan 4.052 makalah. 42 makalah dipertimbangkan untuk analisis teks lengkap. Dari 42 teks lengkap yang dicari, empat diantaranya dimasukkan dalam tinjauan sistematis. Sebanyak 152 dari 230 subjek menunjukkan peningkatan fungsi ereksi melalui skor IIEF-5 setelah transplantasi ginjal. Meta-analisis yang dilakukan terhadap skor IIEF dan kadar Testosteron menunjukkan perbedaan yang signifikan sebelum dan sesudah transplantasi.Kesimpulan: Temuan kami telah mengkonfirmasi bahwa transplantasi ginjal meningkatkan fungsi ereksi. Dengan demikian, peningkatan signifikan dalam skor testosteron dan IIEF pasca transplantasi terbukti secara statistik dalam penelitian ini. Namun, karena jumlah penelitian yang ada terbatas, bukti yang ada pun terbatas. Penelitian lebih lanjut dengan metodologi yang lebih baik dan ukuran sampel yang lebih besar diperlukan untuk menyelidiki pengaruh transplantasi ginjal pada fungsi ereksi.

---

Introduction: Erectile dysfunction (ED) is a major health burden worldwide frequently found in those with end-stage renal disease (ESRD) Although renal transplant improves the problem in some patients, as many as 20 to 50% of recipients continue to suffer ED. To this date, literature regarding the effect of kidney transplantation on ED has been contradictory. Majority of studies have shown that patients regain erectile function following renal transplant, whereas other studies showed minimal effect of transplantation on the status of ED.1,2 We did a systematic review to summarize the effects of kidney transplantation on the status of ED.

Methods: A systematic literature search on PubMed, Cochrane, and Scopus, were carried out in April 2020 by using both free words and MeSH terms. We included all prospective studies investigating the pre- and post-transplant IIEF scores of renal transplant recipients with ED.

Results: The initial database search on PubMed and Google Scholar produced 4,052 papers. 42 papers were considered for full-text analysis. Out of 42 full texts sought, four were included in the systematic review. A total of 152 out of 230 subjects showed improvement of erectile function by means of IIEF-5 score after renal transplantation. Meta-analysis performed on IIEF score and Testosterone level show significant differences pre and post-transplantation.

Conclusion: Our findings have confirmed that renal transplantation improves erectile function. Thus, significant improvement in testosterone and IIEF score post- transplantation were proven statistically in this study. However, as there were only a limited number of studies, the evidence is limited. Further studies with better methodology and larger sample size are needed to investigate the effect of renal transplantation on erectile function."

"Latar Belakang: Aktivasi komplemen dapat menyebabkan respon imun berlebihan dan merupakan salah satu faktor yang berpengaruh terhadap morbiditas serta mortalitas pasien COVID-19. Beberapa penghambat aktivasi komplemen saat ini sedang dipelajari untuk menghambat aktivasi sistem komplemen yang berlebihan pada pasien COVID-19. Resiko, keuntungan, waktu pemberian dan bagian dari sistem yang akan ditargetkan perlu dipertimbangkan pada saat akan menggunakan penghambat komplemen, oleh karena itu telaah sistematis ini dibuat untuk mengambil kesimpulan apakah pemberian terapi penghambat sistem komplemen dapat menurunkan mortalitas pasien COVID-19 yang dirawat di Rumah Sakit berdasarkan penelitian-penelitian yang tersedia.Tujuan: Mengetahui efek pemberian terapi penghambat sistem komplemen terhadap mortalitas pasien COVID-19 yang dirawat di Rumah Sakit.Metode: Dengan menggunakan kata kunci spesifik, dilakukan pencarian artikel potensial secara komprehensif pada PubMed, Embase, Cochrane, dan Scopus database dengan pembatasan waktu 2019 sampai dengan sampai 31 Desember 2022. Protokol studi ini telah diregistrasi di PROSPERO (CRD42022306632). Semua penelitian pemberian terapi penghambat komplemen pada pasien COVID-19 dimasukkan. Analisis statistik dilakukan dengan menggunakan perangkat lunak Review Manager 5.4.Hasil: 5 penelitian memenuhi kriteria dan dimasukkan dalam telaah sistematis serta meta-analisis dengan total 739 pasien COVID-19. Hasil analisis Forest plot menunjukan bahwa pemberian terapi penghambat sistem komplemen menurunkan mortalitas sebesar 28% pada pasien COVID-19 yang dirawat di Rumah Sakit (RR 0,72; 95% CI: 0,46 – 1,14, I2 = 61%, P-value = 0.16).Kesimpulan: Pemberian terapi penghambat sistem komplemen secara statistik tidak signifikan menurunkan mortalitas pada pasien COVID-19 yang dirawat di Rumah Sakit

---

Background: Complement activation can cause an exaggerated immune response and is one of the factors that influence the morbidity and mortality of COVID-19 patients. Several complement activation inhibitors are currently being studied to inhibit excessive complement activation in COVID-19 patients. The risks, benefits, time of administration and the part of the system to be targeted need to be considered when using complement inhibition, therefore this systematic review was made to conclude whether the administration of complement system inhibition therapy can reduce the mortality of COVID-19 patients who are hospitalized based on available studies.

Objective: To determine the effect of complement system inhibitory therapy on the mortality of hospitalized COVID-19 patients

Methods: Using specific keywords, we comprehensively searched the PubMed, Embase, Cochrane, and Scopus databases for potential articles from 2019 to December 31, 2022. The research protocol was registered with PROSPERO (CRD42022306632). All studies administering complement inhibitory therapy to COVID-19 patients were processed. Statistical analysis was performed using Review Manager 5.4 software.

Result: 5 studies met the criteria and were included in a systematic review and meta-analysis of a total of 739 COVID-19 patients. The results of the Forest plot analysis showed that administration of complement system inhibitor therapy reduced mortality by 28% in hospitalized COVID-19 patients (RR 0.72; 95% CI: 0.46 – 1.14, I2 = 61%, P -value = 0.16).

Conclusion: Providing complement system inhibitor therapy did not statistically significantly reduce mortality in hospitalized COVID-19 patients"

"Latar Belakang: Janus Kinase (JAK)-inhibitors telah digunakan untuk terapi beberapa penyakit inflamasi dan autoimun karena kemampuannya untuk mengendalikan respon imun dan cytokine release syndrome. Saat ini penggunaan baru dari Janus Kinase (JAK)-inhibitors diperuntukan untuk terapi coronavirus disease 2019 (Covid-19), namun bukti mengenai kegunaannya masih belum jelas. Penelitian ini dilakukan untuk menganalisa efikasi dari Janus Kinase (JAK)-inhibitors untuk mengurangi mortalitas pasien Covid-19.Tujuan: Mengetahui efek pemberian terapi Janus Kinase (JAK)-inhibitors terhadap mortalitas pasien Covid-19.Metode: Dengan menggunakan kata kunci spesifik, dilakukan pencarian artikel potensial secara komprehensif pada PubMed, Europe PMC, and ClinicalTrials.gov database dengan pembatasan waktu sampai 2 Juni 2021. Semua penelitian tentang Covid-19 dan JAK-inhibitors dimasukan. Analisa statistik dilakukan denganReview Manager 5.4 software.Hasil: 13 penelitian dengan 4339 pasien Covid-19 dimasukan dalam meta-analisis. Data kami menyimpulkan bahwa terapi JAK-inhibitors berhubungan dengan menurunnya mortalitas pasien Covid-19 (RR 0.52; 95%CI: 0.36-0.76, p=0.0006, I2 = 33%, random-effect modelling).Kesimpulan: Penelitian ini menyimpulkan terapi JAK-inhibitors berhubungan dengan menurunnya mortalitas pasien Covid-19. Namun dibutuhkan randomized clinical trials yang lebih banyak untuk mengkonfirmasi hasil penelitian ini.

---

Background: : Janus Kinase (JAK)-inhibitors have been used for treating several inflammatory and autoimmune disease because of its ability to restrains immune systems and cytokine release syndrome. Currently, JAK-inhibitors are repurposed for the treatment of coronavirus disease 2019 (Covid-19), however the evidence regarding their benefit are still unclear. This study sought to analyze the efficacy of JAK-inhibitors in improving the mortality outcomes of Covid-19 patients.

Objective: To determine the effect of JAK-inhibitors as therapy in Covid-19 patients related to mortality.

Methods: Using specific keywords, we comprehensively searched the potential articles on PubMed, Europe PMC, and ClinicalTrials.gov database until June 2nd, 2021. All published studies on Covid-19 and JAK-inhibitors were retrieved. Statistical analysis was conducted using Review Manager 5.4 software.

Results: A total of 13 studies with 4,339 Covid-19 patients were included in the meta-analysis. Our data suggested that JAK-inhibitors was associated with reduction of mortality from Covid-19 (RR 0.52; 95%CI: 0.36 – 0.76, p=0.0006, I2 = 33%, random-effect modelling).

Conclusion: Our study suggests that JAK-inhibitors may offer beneficial effects on Covid-19 mortality. However, more randomized clinical trials warrant to confirm the findings of our study."